Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Feb;46(2):550-5.
doi: 10.1128/AAC.46.2.550-555.2002.

Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

Ian A Critchley  1 , James A Karlowsky, Deborah C Draghi, Mark E Jones, Clyde Thornsberry, Kate Murfitt, Daniel F Sahm
Affiliations

Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

Ian A Critchley et al. Antimicrob Agents Chemother. 2002 Feb.

Abstract

The in vitro activities of faropenem and other antimicrobial agents were determined against 4,725 Streptococcus pneumoniae isolates, 2,614 Haemophilus influenzae isolates, and 1,193 Moraxella catarrhalis isolates collected from 273 U.S. laboratories during 1999. Faropenem MICs at which 90% of isolates are inhibited were 0.008, 0.25, and 1 microg/ml for penicillin-susceptible, -intermediate, and -resistant S. pneumoniae strains, respectively; 0.5 and 1 microg/ml for beta-lactamase-positive and -negative H. influenzae strains, respectively; and 0.12 and 0.5 microg/ml for beta-lactamase-negative and -positive M. catarrhalis strains, respectively. Faropenem holds promise as an oral therapy for community-acquired respiratory tract infections.

PubMed Disclaimer

References

    1. Appelbaum, P. C. 1987. World-wide development of antibiotic resistance in pneumococci. Eur. J. Clin. Microbiol. 6: 367–377. - PubMed
    1. Bartlett, J. G., and L. M. Mundy. 1995. Community-acquired pneumonia. N. Engl. J. Med. 333: 1618–1624. - PubMed
    1. Cormican, M. G., and R. N. Jones. 1995. Evaluation of the in vitro activity of faropenem (SY5555 or SUN5555) against respiratory tract pathogens and beta-lactamase producing bacteria. J. Antimicrob. Chemother. 35: 535–539. - PubMed
    1. Doern, G. V., A. B. Brueggemann, G. Pierce, H. P. Holley, Jr., and A. Rauch. 1997. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of β-lactamase-positive isolates resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antimicrob. Agents Chemother. 41: 292–297. - PMC - PubMed
    1. Edwards, J. R. 1995. Meropenem: a microbiological overview. J. Antimicrob. Chemother. Rev. 36(Suppl A): 1–17. - PubMed

Publication types

MeSH terms